Article Information
History
- July 21, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Author Information
- Goh Ohji1,*,
- Yohei Funakoshi2,#,*,
- Kimikazu Yakushijin2,*,
- Takaji Matsutani3,4,
- Tomoki Sasaki5,
- Takahiro Kusakabe6,
- Sakuya Matsumoto2,
- Taiji Koyama2,
- Yoshiaki Nagatani2,
- Keiji Kurata2,
- Shiro Kimbara2,
- Naomi Kiyota2,7 and
- Hironobu Minami2,7
- 1Division of Infection Disease Therapeutics, Department of Microbiology and Infectious Diseases, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan
- 2Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan
- 3Research & Development Department, Repertoire Genesis Inc., Ibaraki, Japan
- 4Translational Research Dept. Maruho Co., Ltd., Kyoto, Japan
- 5R&D Department, KAICO Ltd., Fukuoka, Japan
- 6Laboratory of Insect Genome Science, Graduate School of Bioresource and Bioenvironmental Sciences, Kyushu University, Fukuoka, Japan
- 7Cancer Center, Kobe University Hospital, Kobe, Japan
- ↵#Corresponding author
: Yohei Funakoshi, M.D., Ph.D. Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, E-mail: yohei{at}med.kobe-u.ac.jp, Phone: +81-78-382-5820, Fax: +81-78-382-5821
↵* G.O., Y.F. and K.Y contributed equally to this work.
Posted July 21, 2024.
Analysis of B-cell receptor repertoire to evaluate the immunogenicity of SARS-CoV-2 RBD mRNA vaccine: MAFB-7256a (DS-5670d)
